Pradaxa Lawsuit Lawyers
Each year hundreds of thousands are prescribed blood thinners in an attempt to prevent blood clotting and stroke.
In fact, medical experts estimate the anti-coagulant drug industry is selling between $10 and $20 billion of anti-coagulant drugs per year.
Over the last year and a half individuals across the United States have been prescribed Pradaxa. Some have had adverse reactions. Today we write to you.
If you have taken Pradaxa (dabigatran) and have experienced internal bleeding, call our Law Firm for we may be able to help you receive financial compensation for your damages, for your losses for any side effects and injuries, medical bills, lost wages and other damages.
Pradaxa was introduced by Boehringer Ingelheim, a German pharmaceutical company, in 2010 as a revolutionary blood thinner to prevent strokes among patients suffering from atrial fibrillation. In that same year, Boehringer Ingelheim acknowledged a link between the new drug and at least 260 deaths and other complications, particularly among elderly users. However, they considered the relatively low number of deaths a "reasonable order of magnitude." Why was the drug ultimately approved? Because the benefits were seen to outweigh the risks; we believe they chose profits over people.
While all blood thinners carry a risk of gastrointestinal bleeding, Pradaxa appears to carry a greater risk than originally stated on the warning label. In fact, many critics have questioned the clinical trials used to gain FDA approval. Pradaxa was approved based on a clinical study known as RE-LY, which compared Pradaxa with warfarin (coumadin), a popular blood thinner that has been on the market for decades.